comprehensive -WSS

comprehensive

author：comprehensive 2025-09-29 01:07:07 - browse：3926

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Generate Biomedicines machine learning biotech raises $273M

Wikipedia

explore

WSS

Americans' trust in science, scientist continues decline: Report

STAT letters to the editor on burnt

Hospitals consider fixing cancer drug shortages on their own

Long Covid needs a new name — and a new frame

Long Covid needs a new name — and a new frame

A common UTI test for kids haunts adults as a traumatic 'nightmare'

hotspot

comprehensive

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Spinal cord stimulation reduces pain in amputees, study finds

United colonoscopy coverage change 'may cost lives,' doctors say

FDA proposes changes to key medical devices approval pathway

Novavax promises a turnaround & Lilly roils the obesity market

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Hollywood unions extend contract negotiations for actors

Patients' immediate access to test results puts radiologists in a bind

Affirmative action in medical school literally saved lives

FDA needs staff influx to meet gene therapy needs, Marks says

hotspot

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

What to make of Biden’s latest efforts on cancer research

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Americans' trust in science, scientist continues decline: Report

STAT letters to the editor on burnt

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Wikipedia

explore

focus

entertainment